Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05814523
Study type Interventional
Source Marinus Pharmaceuticals
Contact
Status Withdrawn
Phase Phase 3
Start date March 2024
Completion date August 2024

See also
  Status Clinical Trial Phase
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Recruiting NCT06344338 - Application of tDCS Stimulation in Controlling Refractory Status Epilepticus N/A
Not yet recruiting NCT05830864 - Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus
Not yet recruiting NCT05684978 - Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus Phase 4
Recruiting NCT05851391 - buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest Phase 2
Recruiting NCT05934903 - Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus N/A
Completed NCT04333082 - Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction